LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced data from a planned interim analysis of the LATITUDE phase III trial, indicating that their long-acting injectable antiretroviral treatment (ART) for HIV, Cabenuva (cabotegravir + rilpivirine), demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of ART adherence c ...

LONDON--(BUSINESS WIRE)--Today, ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the American Academy of HIV Medicine (AAHIVM) jointly announced the launch of The Dr. Dawn K. Smith HIV Prevention Clinical Fellowship. The fellowship will provide comprehensive HIV training to non-infectious disease clinicians serving communities disproportionately affected by HIV. The fellowship was announced at the Conference on Retroviruses and Opportuni ...

Pfizer Inc. (NYSE:PFE) TD Cowen 44th Annual Health Care Conference March 4, 2024 11:10 AM ET Company Participants David Denton - Chief Financial Officer and Executive Vice President Conference Call Participants Steve Scala - TD Cowen Steve Scala Well, good morning once again. We're delighted to have Pfizer here at Cowen's 44th Annual Healthcare Conference. Representing the company, Dave Denton, who is Chief Financial Officer as well as Executive Vice President, will start out. Dave is going to give a few th ...

Pfizer Inc. (NYSE:PFE) TD Cowen 44th Annual Health Care Conference March 4, 2024 11:10 AM ET Company Participants David Denton - Chief Financial Officer and Executive Vice President Conference Call Participants Steve Scala - TD Cowen Steve Scala Well, good morning once again. We're delighted to have Pfizer here at Cowen's 44th Annual Healthcare Conference. Representing the company, Dave Denton, who is Chief Financial Officer as well as Executive Vice President, will start out. Dave is going to give a few th ...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from its phase I study showing that an investigational formulation of cabotegravir, known as cabotegravir ultra long-acting (CAB-ULA), can be dosed at intervals of at least four months. This is the company’s first step towards delivering ultra long-acting injectable HIV treatment and prevention medicines that would potentially enable p ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this drugmaker have returned -1.3% over the past month versus the Zacks S&P 500 composite's +4.8% change. The Zacks Large Cap Pharmaceuticals industry, to which Pfizer belongs, has gained 6% over this period. Now the key question is: Where could the stock be headed in the near term?Although media reports or r ...

olm26250 Introduction Over the past few weeks, I have often told people I'm getting a 2021 feeling, as the market is rapidly rising, boosted by a few select tech/growth stocks. Meanwhile, crypto assets are flying again, boosted by Federal Reserve rate expectations that may not be fully justified in light of sticky inflation. The other day, Bloomberg wrote an article titled The Casino Crowd Is Back Across Markets With Soft Echoes Of 2021." According to the article, retail investors, who largely remained ...

Keep winners, ditch losers. That's usually not bad advice for investors. There's one big problem, though: Sometimes long-term winners temporarily look like losers.Even the biggest and the best companies can undergo periods when things just don't go their way. One especially comes to mind for me. Here's an S&P 500 dividend stock down 56% to buy and hold forever.The main culprit behind the PfizzleI won't prolong the suspense. The stock I'm talking about is Pfizer (PFE 0.11%). And it has admittedly been a lose ...

Given its key role in the fight against COVID-19, the fact that Pfizer (PFE 0.11%) shares are down 56% from their 2021 peak isn't entirely surprising. Demand for its COVID-19 vaccine (Comirnaty) and its treatment (Paxlovid) soared during the pandemic's height. With the coronavirus contagion abating in the meantime, though, last year's sales fell 41%. Income fell more than 70% year over year. Yikes.However, the stock's sellers have arguably overshot their target. Pfizer stock is not only now well undervalued ...

2024年初，全球医药行业的领军企业陆续发布了2023年财报。亿欧大健康紧密关注的15家跨国医药公司（MNC）中，强生以全球852亿美元的总营收脱颖而出，罗氏和默沙东紧随其后。而去年还以超过千亿美元的营收占据行业头名的辉瑞，今年未能保持*地位，遗憾地退出了前三的行列。 从增速来看，强生、赛诺菲、阿斯利康、诺华、礼来、诺和诺德、安进等11家公司均实现了营收的正增长。相比之下，辉瑞、艾伯维、BMS、吉利德等公司的增长速度有所放缓。 这一轮医药公司的财报发布不仅为全球医药市场带来了新的竞争格局和看点，也揭示了医药行业的未来发展趋势。在这场激烈的竞争中，哪些公司能够抓住机遇，持续创新布局，将成为业界关注的焦点。 01  全球制药TOP3洗牌，辉瑞跌出前三 强生在完成消费者保健业务的分拆后，继续延续2023上半年*的强劲势头，以全年852亿美元营收占据榜首，其制药业务共实现营收547.59亿美元，同比增长4.2%。这一增长主要得益于自身免疫、肿瘤、神经科学、感染、肺动脉高压、心血管及代谢等领域的强劲表现。其中，自免与肿瘤学业务分别贡献了180.52亿和176.61亿美元营收，增长率分别达到了6.6%和10.5%，是拉 ...